Hosted on MSN51s
FTSE 100 Live 24 February: Just Eat backs £3.4bn takeover, B&M profit downgrade as boss quitsBAE Systems rallied 29.5p to 1285p, alongside drugs giant GSK as shares put on 24.5p to 1453.5p after completing the acquisition of Boston-based, clinical-stage biopharmaceutical company IDRx. The ...
GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.
The FTSE 250 business's stock jumped 4.7%, or 6.3p, to 141.8p as investors bet it could be next food delivery group to be ...
GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical ...
GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated ...
GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, ...
(Alliance News) - Stock prices in London opened mostly flat on Monday, while across the channel Germany's election results have sparked uncertainty but also hopes of economic stimulus. The FTSE 100 ...
It forecasts that the repurchases - which are due to complete in 18 months - will boost core earnings by 6% to 8% in 2025 ...
GSK on Monday also said it has start the GBP2 billion buyback programme that it announced earlier this month, starting with an initial GBP700 million tranche.
GSK’s share price has fallen a long way on a combination of factors, but do its recent strong results leave its current price looking cheap to me?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results